secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2022-09-28T23:59:59+00:00
Accession:  0001387131-22-010041
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences appoints Kevin Danahy as CEO; grants 450,000 share option
---------------------------------------------------------------------------

- Kevin Danahy, previously Chief Commercial Officer, named CEO effective September 20, 2022.
- Annual base salary of $400,000 and target bonus up to 100% of base salary.
- Received option to acquire 450,000 shares vesting over 4 years at closing price on grant date.
- Amended employment agreement includes 24-month severance if terminated within 2 years.
- Danahy brings 20+ years medtech experience from Intuitive Surgical, Zimmer Biomet, Medtronic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000138713122010041/0001387131-22-010041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000138713122010041/pulse-8k_092322.htm
  HTML page:      https://secwatch.observer/filing/0001387131-22-010041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer